Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06984328 2026-05-05

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

1 enrolled

Dermatologic

Melanoma, Recurrence

NCT05359445 2026-04-30

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Phase 1 Active not recruiting

95 enrolled

Neoplasms, Recurrence

NCT03618550 2026-04-16

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Recruiting

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT01822652 2026-04-06

GRAIN

Phase 1 Active not recruiting

11 enrolled

CNS

Neuroblastoma, Recurrence

NCT05047094 2026-04-06

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Phase NA Recruiting

48 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

6 enrolled

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Phase EARLY_PHASE1 Completed

22 enrolled

Lymphoid

Lymphoma, Neoplasms, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Phase 2 Recruiting

15 enrolled

Recurrence

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT05084430 2026-01-22

Study of Pembrolizumab and M032 (NSC 733972)

Phase 1/2 Recruiting

28 enrolled

CNSSarcoma

Astrocytoma, Glioblastoma, Recurrence, Gliosarcoma

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

Phase 1/2 Completed

16 enrolled 14 charts

Lymphoid

Burkitt Lymphoma, Recurrence

NCT04220866 2025-10-29

MK-1454-002

Phase 2 Completed

18 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03383094 2025-10-07

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Phase 2 Active not recruiting

126 enrolled

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05263492 2025-10-02